Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors

Review Infectious Diseases

Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals: a systematic review

Tom Jefferson et al.

Summary: Studies have shown highly variable transmission rates, indicating the potential for SARS-CoV-2 transmission from pre-symptomatic and asymptomatic individuals.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Infectious Diseases

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

Anika Singanayagam et al.

Summary: Vaccination reduces the risk of delta variant infection and accelerates viral clearance. However, fully vaccinated individuals with breakthrough infections may still have similar peak viral loads as unvaccinated cases and can efficiently transmit the infection.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California

Kristin L. Andrejko et al.

Summary: Vaccination with mRNA-based vaccines in California has shown to effectively prevent documented SARS-CoV-2 infections, with similar effectiveness for BNT126b2 and mRNA-1273. However, vaccine hesitancy poses a challenge in achieving the necessary coverage levels for herd immunity.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting

Adeel A. Butt et al.

Summary: The study evaluated the short-term effectiveness of SARS-CoV-2 vaccines in preventing infection in a real-world setting. The results showed that the currently used vaccines are highly effective in preventing confirmed infection in a high-risk population, whether it is the Pfizer-BioNTech BNT-162b2 vaccine or the Moderna mRNA-1273 vaccine.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021

Jefferson M. Jones et al.

Summary: A study based on blood donations in the US from July 2020 to May 2021 found that seroprevalence of SARS-CoV-2 antibodies induced by vaccination or infection increased over time and varied by age, race and ethnicity, and geographic region. Despite adjustments for demographic differences, the findings may not be fully representative of the entire US population.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Real world effectiveness of covid-19 vaccines Rigorous studies of these vaccines in action are an urgent priority globally

Daniel Hungerford et al.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Public, Environmental & Occupational Health

COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021

Meseret Birhane et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

Eli S. Rosenberg et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Wesley H. Self et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Immunology

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

John S. Tregoning et al.

Summary: The development and rollout of vaccines have brought hope for controlling the COVID-19 pandemic, with vaccines proving highly effective in preventing disease. However, challenges remain in ensuring equitable access to vaccines globally, as well as lessons to be learned for controlling pandemics in the future.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors

Related references

Export Citation

Share Paper